Our Signal‑First™ Platform

We map skin‑relevant signaling nodes and design topical ligands/peptides that gently bias those nodes toward resilience.

Focus Areas:

1. Barrier Intelligence – Upregulate lipid handling and tight‑junction harmony; 
2. Calm & Balance – Tame inflammaging signals
3. Matrix Renewal – Encourage a youthful ECM balance by supporting pro‑collagen expression and reining in excess MMP activity; improve dermal density aesthetics.
4. Dynamics of hydration, signaling, and cell‑matrix dialog.
5. UV/Urban Stress Response – Antioxidant‑signaling support and mitochondrial comfort to reduce the look of fatigue and uneven tone.

How we build it

• In‑silico design (molecular motifs, docking heuristics for topical targets)
• Peptide synthesis 
• Delivery engineering (ethosomes/liposomes/film‑forming gels)
• Bench to user (3D skin models → dermatologist‑supervised HRIPT/user studies)

Regulatory stance: We design cosmetic technologies under EU Reg. 1223/2009 claim‑substantiation principles and dermatological test standards.

The HIVCAM Assay is Bernann Biotech innovative in vitro testing platform that combines human skin tissue with the chorioallantoic membrane (CAM). This hybrid model offers a vascularized, living environment to evaluate cosmetic formulations for irritation, healing, and efficacy—all without the use of live mammals.

It enables rapid, ethically compliant testing aligned with 3Rs principles, providing human-relevant data for product safety and performance.

Ideal for:

• Irritation & inflammation profiling
• Wound healing & regeneration
• Anti-aging and collagen-boosting actives
• Pigmentation and skin tone modulation

Fast. Ethical. Predictive.
Hivcam bridges the gap between static cell cultures and traditional animal models—bringing your cosmetic innovation closer to the skin.